{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464383196
| IUPAC_name = 3-(Cyclopropylmethoxy)-''N''-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
| image = Roflumilast structure.svg
| width = 240
| image2 = Roflumilast ball-and-stick model.png
| width2 = 240

<!--Clinical data-->
| tradename = Daxas, Daliresp
| Drugs.com = {{drugs.com|CDI|roflumilast}}
| MedlinePlus = a611034
| licence_EU = Daxas
| licence_US = Roflumilast
| pregnancy_AU = B3
| pregnancy_US = C
| pregnancy_category =  
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 79%<ref name = DM/><ref name = EMC/><ref name = EMA/><ref name = MSR/>
| protein_bound = 99%<ref name = DM/><ref name = EMC/><ref name = EMA/><ref name = MSR/>
| metabolism = [[Hepatic]] via [[CYP1A2]] & [[CYP3A4]]<ref name = DM/><ref name = EMC/><ref name = EMA/><ref name = MSR/>
| elimination_half-life = 17 hours (30 hours [active metabolite])<ref name = DM/><ref name = EMC/><ref name = EMA/><ref name = MSR/>
| excretion = Urine (70%)<ref name = DM/><ref name = EMC/><ref name = EMA/><ref name = MSR/>

<!--Identifiers-->
| IUPHAR_ligand = 6962
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 162401-32-3
| ATC_prefix = R03
| ATC_suffix = DX07
| PubChem = 449193
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 395793
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 47657
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0P6C6ZOP5U
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 193240

<!--Chemical data-->
| C=17 | H=14 | Cl=2 | F=2 | N=2 | O=3 
| molecular_weight = 403.207 g/mol
|  smiles = C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = MNDBXUUTURYVHR-UHFFFAOYSA-N
}}

'''Roflumilast''' (trade names '''Daxas''', '''Daliresp''') is a drug that acts as a selective, long-acting [[Phosphodiesterase-4 inhibitor|inhibitor of the enzyme phosphodiesterase-4]] (PDE-4). It has [[anti-inflammatory]] effects and is used as an orally administered drug for the treatment of inflammatory conditions of the lungs such as [[chronic obstructive pulmonary disease]] (COPD).<ref name="pmid18044684">{{cite journal
| last1 = Boswell-Smith | first1 = V
| last2 = Spina | first2 = D
| title = PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
| journal = [[International Journal of Chronic Obstructive Pulmonary Disease]]
| volume = 2
| issue = 2
| pages = 121–9
| year = 2007
| pmid = 18044684
| pmc = 2695611
| url = http://www.dovepress.com/getfile.php?fileID=971
| issn = 1178-2005
}}</ref><ref name="pmid18307529">{{cite journal
| last1 = Herbert | first1 = C
| last2 = Hettiaratchi | first2 = A
| last3 = Webb | first3 = DC
| last4 = Thomas | first4 = PS
| last5 = Foster | first5 = PS
| last6 = Kumar | first6 = RK
| title = Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma
| journal = [[Clinical & Experimental Allergy]]
| volume = 38
| issue = 5
| pages = 847–56
|date=May 2008
| pmid = 18307529
| doi = 10.1111/j.1365-2222.2008.02950.x
| issn = 1365-2222
}}</ref><ref name="pmid18374614">{{cite journal
| last1 = Hohlfeld | first1 = JM
| last2 = Schoenfeld | first2 = K
| last3 = Lavae-Mokhtari | first3 = M
| last4 = Schaumann | first4 = F
| last5 = Mueller | first5 = M
| last6 = Bredenbroeker | first6 = D
| last7 = Krug | first7 = N
| last8 = Hermann | first8 = R
| title = Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial
| journal = [[Pulmonary Pharmacology & Therapeutics]]
| volume = 21
| issue = 4
| pages = 616–23
|date=August 2008
| pmid = 18374614
| doi = 10.1016/j.pupt.2008.02.002
| issn = 1094-5539
}}</ref><ref name="pmid18447606">{{cite journal
| last1 = Field | first1 = SK
| title = Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma
| journal = [[Expert Opinion on Investigational Drugs]]
| volume = 17
| issue = 5
| pages = 811–8
|date=May 2008
| pmid = 18447606
| doi = 10.1517/13543784.17.5.811	
| issn = 1354-3784
}}</ref>

In June 2010, Daxas was approved in the [[European Union|EU]] for severe COPD associated with chronic bronchitis.<ref>[http://www.genengnews.com/gen-news-highlights/nycomed-s-anti-inflammatory-gains-approval-in-eu-for-copd/81243622/ "Nycomed's Anti-Inflammatory Gains Approval in EU for COPD"]</ref> In March 2011, Daliresp gained FDA approval in the [[United States|US]] for reducing COPD exacerbations.<ref>{{cite press release
| url = http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm244989.htm
| title = FDA approves new drug to treat chronic obstructive pulmonary disease
| date = March 1, 2011
| publisher = [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA)
}}</ref>

==Medical uses==
Its primary clinical use is in the prevention of exacerbations (lung attacks) in severe COPD.<ref name = DM>{{cite web|title=DALIRESP (roflumilast) tablet [Forest Laboratories, Inc.]|work=DailyMed|publisher=Forest Laboratories, Inc.|date=August 2013|accessdate=18 November 2013|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95519b97-d0a6-4c9f-baf0-bc5da08296c7|format=PDF}}</ref><ref name = EMC>{{cite web|title=DAXAS 500 micrograms film-coated tablets|work=electronic Medicines Compendium|publisher=Takeda UK Ltd|date=9 September 2013|url=http://www.medicines.org.uk/emc/medicine/23416/SPC/DAXAS+500+micrograms+film-coated+tablets/|accessdate=18 November 2013}}</ref><ref name = EMA>{{cite web|title=Daliresp : EPAR - Product Information|work=European Medicines Agency|publisher=Takeda GmbH|date=26 September 2013|accessdate=18 November 2013|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002398/WC500103078.pdf|format=PDF}}</ref><ref name = MSR>{{cite web|title=roflumilast (Rx) - Daliresp|work=Medscape Reference|publisher=WebMD|accessdate=18 November 2013|url=http://reference.medscape.com/drug/daliresp-roflumilast-999626}}</ref>

==Adverse effects==

Common (1–10% incidence) adverse effects include:<ref name = DM/><ref name = EMC/><ref name = EMA/><ref name = MSR/><ref name="pmid18660825">{{cite journal| last1 = Spina | first1 = D| title = PDE4 inhibitors: current status| journal = [[British Journal of Pharmacology]]| volume = 155| issue = 3| pages = 308–15|date=October 2008| pmid = 18660825| pmc = 2567892| doi = 10.1038/bjp.2008.307| issn = 1476-5381}}</ref>
* Diarrhea
* Weight loss
* Nausea
* Headache
* Insomnia
* Decreased appetite
* Abdominal pain
* Rhinitis
* Sinusitis
* Urinary tract infection
* Depression

==References==
{{Reflist}}


{{Drugs for obstructive airway diseases}}
{{Phosphodiesterase inhibitors}}

[[Category:Benzamides]]
[[Category:Chloropyridines]]
[[Category:Organofluorides]]
[[Category:PDE4 inhibitors]]
[[Category:Phenol ethers]]
[[Category:Cyclopropanes]]